Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin - 10/08/11
, Jagadeesh Bayry, DVM, PhD a, b, c, e, ⁎ 
Reprint requests: Jagadeesh Bayry, DVM, PhD, or Srini V. Kaveri, DVM, PhD, INSERM U 872, Equipe 16-Centre de Recherche des Cordeliers, 15 rue de l’Ecole de Médicine, Paris, F-75006, France.Abstract |
Background |
TH17 cells play a critical role in the pathogenesis of several autoimmune and allergic diseases. Intravenous immunoglobulin (IVIg), a therapeutic preparation of polyclonal IgG that is increasingly used in the treatment of diverse autoimmune and allergic diseases, might target TH17 cells to exert therapeutic effects.
Objective |
We sought to examine whether IVIg interferes with the development and function of human TH17 cells.
Methods |
TH17 cells were differentiated from naive human CD4+ T cells in the presence of TGF-β and IL-21. TH17 cells were amplified by stimulating memory CD4+ T cells in the presence of IL-1β and IL-6. The effect of IVIg was examined on the differentiation and amplification of TH17 cells, expression of the TH17 lineage-specific transcription factor retinoic acid-related orphan receptor C, secretion of TH17 effector cytokines, and phosphorylation of signal transducer and activator of transcription 3, a transcription factor that plays an important role in TH17 cell development and function.
Results |
IVIg inhibits the differentiation and amplification of human TH17 cells, as well as the production of their effector cytokines IL-17A, IL-17F, IL-21, and CCL20. The inhibitory effects of IVIg on TH17 cells are F(ab′)2 dependent and involve interference with the expression of retinoic acid-related orphan receptor C and activation of signal transducer and activator of transcription 3. Also, IVIg significantly enhanced forkhead box protein 3–positive regulatory T cells among the memory CD4+ T cells.
Conclusion |
These results reveal a novel mechanism of action of IVIg in achieving a therapeutic effect in autoimmune and allergic diseases, in which TH17 cells play a key modulatory role in sustaining the chronic inflammatory response. Our results also suggest a reciprocal regulation of TH17 and regulatory T-cell populations by IVIg.
Le texte complet de cet article est disponible en PDF.Key words : Intravenous immunoglobulin, allergy, autoimmunity, inflammation, TH17 cells, IL-17, regulatory T cells, retinoic-acid-related orphan receptor C, forkhead box protein 3
Abbreviations used : APC, Foxp3, HSA, IVIg, pSTAT3, RORC, STAT3, Treg
Plan
| Supported by grants from Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université Pierre et Marie Curie, Université Paris Descartes, the European Community’s Seventh Framework Programme (FP7-2007-2013) under Grant Agreement no. HEALTH-F2-2010-260338-ALLFUN, and Octapharma, Lachen, Switzerland. |
|
| Disclosure of potential conflict of interest: S. V. Kaveri and J. Bayry have received research support from Octapharma. The rest of the authors have declared that they have no conflict of interest. |
Vol 127 - N° 3
P. 823 - mars 2011 Retour au numéro
Article précédent
- Characterization of a novel human mast cell line that responds to stem cell factor and expresses functional FcεRI
- Tanya M. Laidlaw, John W. Steinke, Adrienne M. Tiñana, Chunli Feng, Wei Xing, Bing K. Lam, Sailaja Paruchuri, Joshua A. Boyce, Larry Borish
- More alternative activation of macrophages in lungs of asthmatic patients
- Barbro N. Melgert, Nick H. ten Hacken, Bea Rutgers, Wim Timens, Dirkje S. Postma, Machteld N. Hylkema
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?